NCT07423481

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

SEMAFOLLOW - Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity: Observational, National Cohort, Real-world Study in France

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 3,000 (estimated)
• Sponsor: Nantes University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.

Conditions

• Obesity & Overweight

Interventions

Type	Name	Description
OTHER	SEMAFOLLOW questionnaire	If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes

Timeline

• Start date: 2026-06-01
• Primary completion: 2027-03-01
• Completion: 2027-03-01
• First posted: 2026-02-20
• Last updated: 2026-02-27

Locations

1 site across 1 country: France